{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:28:23Z","timestamp":1787239703231,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jtha.2023.09.011","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T19:50:22Z","timestamp":1695325822000},"page":"3490-3500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Functional determination of emicizumab in presence of factor VIII activity"],"prefix":"10.1016","volume":"21","author":[{"given":"Nasim Shahidi","family":"Hamedani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk Anna Marie Therese","family":"Donners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"van Luin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Gasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"R\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsin","family":"EL Amrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"P\u00f6tzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.09.011_bib1","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.09.011_bib2","first-page":"691","article-title":"Acquired haemophilia A: a review of what we know","volume":"13","author":"Mingot-Castellano","year":"2022","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2023.09.011_bib3","first-page":"209","article-title":"Asymptomatic joint bleeding and joint health in hemophilia: a review of variables, methods, and biomarkers","volume":"12","author":"Gooding","year":"2021","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2023.09.011_bib4","first-page":"344","article-title":"Diagnosis and treatment of hemophilia","volume":"17","author":"Kizilocak","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.jtha.2023.09.011_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.011_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"Ljung","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2023.09.011_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.011_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.011_bib9","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.011_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ejh.13490","volume":"105","author":"Nougier","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2023.09.011_bib11","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.011_bib12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14177","article-title":"Effects of emicizumab on APTT, FVIII assays and FVIII inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise","volume":"26","author":"Lowe","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.011_bib13","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"M\u00fcller","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.011_bib14","doi-asserted-by":"crossref","first-page":"O204","DOI":"10.1111\/ijlh.13518","article-title":"Measurement of antifactor VIII antibody titre in the presence of emicizumab; use of chromogenic Bethesda assays","volume":"43","author":"Bowyer","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2023.09.011_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12725","article-title":"Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: a method validation study","volume":"6","author":"Donners","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.011_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115163","article-title":"Development of simple and rapid method for emicizumab quantification by LC-MS\/MS in human plasma","volume":"223","author":"Josset","year":"2023","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.jtha.2023.09.011_bib17","first-page":"248","article-title":"Standing Commission Labor (STAEKOLA) of the Society of Thrombosis and Haemostasis Research (GTH). An update on laboratory diagnostics in haemophilia A and B","volume":"42","author":"M\u00fcller","year":"2022","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2023.09.011_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.transci.2019.08.008","article-title":"Hemophilia A with inhibitor: immune tolerance induction (ITI) in the mirror of time","volume":"58","author":"Nakar","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2023.09.011_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.011_bib20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A\u00a0prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.011_bib21","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.09.011_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1515\/cclm-2020-0696","article-title":"Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma","volume":"59","author":"Tripodi","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2023.09.011_bib23","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1111\/hae.13700","article-title":"Heat inactivation of extended half-life factor VIII concentrates","volume":"25","author":"Fylling","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.011_bib24","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/hae.13901","article-title":"Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life haemophilia treatment products","volume":"26","author":"Payne","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.011_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hae.13001","article-title":"A\u00a0world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE","volume":"22","author":"Turecek","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.011_bib26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A\u00a0critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.011_bib27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/rth2.12421","article-title":"Monitoring standard and extended half-life products in hemophilia: assay discrepancies for factor VIII and IX in pre- and postinfusion samples","volume":"4","author":"Augustsson","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.011_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.011_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13435","article-title":"Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels","volume":"24","author":"Boylan","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.011_bib30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/hae.12646","article-title":"A\u00a0longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients","volume":"21","author":"Montalv\u00e3o","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.011_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103343","article-title":"Revealing and IgG4 analysis to factor VIII in haemophilia-A patients with and without inhibitors","volume":"61","author":"Awasthi","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2023.09.011_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2023.09.011_bib33","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.4161\/mabs.29883","article-title":"In\u00a0vitro and in\u00a0vivo modifications of recombinant and human IgG antibodies","volume":"6","author":"Liu","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.jtha.2023.09.011_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2019.03.006","article-title":"Modifications of recombinant monoclonal antibodies in\u00a0vivo","volume":"59","author":"Liu","year":"2019","journal-title":"Biologicals"},{"key":"10.1016\/j.jtha.2023.09.011_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/antib8010018","article-title":"Macro- and micro-heterogeneity of natural and recombinant IgG antibodies","volume":"8","author":"Beck","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jtha.2023.09.011_bib36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/jcp.41.5.562","article-title":"Artificial factor VIII deficient plasma: preparation using monoclonal antibodies and its use in one stage coagulation assays","volume":"41","author":"Hornsey","year":"1988","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtha.2023.09.011_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271330","article-title":"Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels","volume":"17","author":"Hamedani","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2023.09.011_bib38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ijlh.12552","article-title":"A\u00a0variation of the Nijmegen-Bethesda assay using heat or a novel heat\/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity","volume":"38","author":"Millner","year":"2016","journal-title":"Int J Lab Hematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:40:16Z","timestamp":1761536416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623007134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1538783623007134"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.011","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional determination of emicizumab in presence of factor VIII activity","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}